Boehringer Ingelheim launches LENZELTA mastitis vaccine in the EU dairy market
Boehringer Ingelheim says LENZELTA is being launched in several EU countries from April 2026. The company positions the vaccine as a new prevention tool against clinical mastitis in dairy cows and heifers.
Boehringer Ingelheim announced on April 13 that it is launching LENZELTA, a new bovine mastitis vaccine, in several European Union countries from April 2026. The company says the product is designed for dairy cows and heifers and is intended to reduce both the incidence and the severity of clinical mastitis, one of the costliest health problems in milk production.
The company states that LENZELTA targets two of the pathogens that cause major losses on dairy farms, Staphylococcus aureus and Escherichia coli. Boehringer says the vaccine is given in two doses during the dry-off period, when cows are between lactations and management decisions have an outsize effect on udder health at the next calving.
According to the launch note, the timing is meant to provide an early onset of immunity and protection for up to six months, covering the period when cows are particularly vulnerable around calving and early lactation. Boehringer also says the vaccine uses an oil-free adjuvant and will be sold in several vial sizes so veterinarians can fit it into routine herd-health programs.
The company framed the product as an economic as well as a veterinary tool. Mastitis reduces milk quality and milk volume, harms udder health and can become one of the biggest avoidable losses in a dairy herd. By pushing prevention during the dry-off window, the company argues farmers can stabilize milk output, improve animal well-being and reduce disruption in day-to-day farm operations.
Dr. Gerald Behrens, head of ruminants at Boehringer Ingelheim, said the company sees the vaccine as a new benchmark in mastitis prevention. While the announcement is a corporate release rather than an independent field report, it is still notable for European dairy producers because it signals a new commercial prevention option entering the EU market at a time when mastitis control remains central to herd profitability.